AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies

Conditions

• Lung Cancer
• Targeted Therapy

Interventions

• DRUG: AZD9291

Sponsor

Oslo University Hospital

Collaborators

• [object Object]